CTAG1B and ovarian carcinoma: Several therapeutic ovarian cancer vaccine strategies have been employed using whole tumor homogenate strategies as well as approaches involving targeted immunity against tumor associated antigens (TAA) overexpressed in ovarian malignancies including human epidermal growth factor receptor 2 (HER2), cancer-testis antigen 1 (CTAG1B or NY-ESO-1), or cancer antigen 25 (CA-125) [5].